Clinically significant pharmacokinetic drug interactions with benzodiazepines

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 5, 1999, Pages 347-355

  Tanaka, E ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIULCER AGENT; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; BROTIZOLAM; CHLORDIAZEPOXIDE; CIMETIDINE; CLONAZEPAM; CLOTIAZEPAM; CYTOCHROME P450 ISOENZYME; DIAZEPAM; ETIZOLAM; FLURAZEPAM; FLUTAZOLAM; LORAZEPAM; LORMETAZEPAM; MACROLIDE; MEDAZEPAM; MIDAZOLAM; NIMETAZEPAM; NITRAZEPAM; ORAL CONTRACEPTIVE AGENT; OXAZEPAM; PRAZEPAM; SEROTONIN UPTAKE INHIBITOR; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DEMETHYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; HUMAN; ORAL DRUG ADMINISTRATION; REDUCTION; REVIEW;

ANIMALS; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; DRUG INTERACTIONS; HUMANS;

EID: 0032735971     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00247.x     Document Type: Review

References (95)

1. 1. Ketter TA, Flockhart DA, Post RM, et al. (1995) The emerging role of cytochrome P450, 3A in psychopharmacology. Journal of Clinical Psychopharmacology, 15, 387-398.
2. 2. Ameer B, Weintraub RA. (1997) Drug interactions with grapefruit juice. Clinical Pharmacokinetics, 33, 103-121.
3. 3. Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clinical Pharmacokinetics, 33, 454-471.
4. 4. Michalets EL. (1998) Update. Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy, 18, 84-112.
5. 5. Tanaka E. (1998) Clinically important pharmacokinetic drug-drug interactions. Role of cytochrome P450 enzymes. Journal of Clinical Pharmacy and Therapeutics, 24, 403-416.
6. 6. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89-96.
7. 7. Yasumori T, Nagata K, Yang SK, et al. (1993) Cytochrome P450 mediated metabolism of diazepam in human and rat. involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics, 3, 291-301.
8. 8. Andersson T, Miners JO, Veronese MH, Birkett DJ. (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology, 38, 131-137.
9. 9. Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. (1994) Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23-31.
10. 10. Ihara N, Kokufu T, Sugioka N, Ohta T, Nosaka K. (1993) Inhibitory effect of diltiazem on diazepam metabolism in the mouse hepatic microsomes. Biological and Pharmaceutical Bulletin, 16, 331-333.
11. 11. Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA. (1993) Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundamental and Clinical Pharmacology, 7, 69-75.
12. 12. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clinical Pharmacology and Therapeutics, 45, 348-355.
13. 13. Hoyumpa AM, Patwardhan R, Maples M, et al. (1981) Effect of short-term ethanol administration on lorazepam clearance. Hepatology, 1, 47-53.
14. 14. Griffin RJ, Burka LT, Demby KB. (1995) Oxidative biotransformation of oxazepam to reactive and nonreactive products in rat, mouse and human microsomes. Human and Experimental Toxicology, 14, 779-786.
15. 15. Antal EJ, Ereshefsky L, Wells B, et al. (1986) Multicenter evaluation of the kinetic and clinical interaction of alprazolam and imipramine. Clinical Pharmacology and Therapeutics, 39, 178.
16. 16. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ. (1991) Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology, 104, 323-327.
17. 17. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN. (1992) A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy, 12, 103-106.
18. 18. Ring BJ, Binkley SN, Roskos L, Wrighton SA. (1995) Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1′-hydroxy midazolam formation in vitro. Journal of Pharmacology and Experimental Therapeutics, 275, 1131-1135.
19. 19. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF. (1988) The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clinical Pharmacology and Therapeutics, 43, 412-419.
20. 20. Moskowitz H, Burns M. (1988) The effects on performance of two antidepressants, alone and in combination with diazepam. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 12, 783-792.
21. 21. Fleishaker JC, Hulst LK. (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. European Journal of Clinical Pharmacology, 46, 35-39.
22. 22. van Harten J, Holland RL, Wesnes K. (1992) Influence of multipl-dose administration of fluvoxamine on the pharmacokinetics of the benzodiazepine bromazepam and lorazepam: a randomized, cross-over study [Abstract]. European Neuropsychopharmacology, 2, 381.
23. 23. Perucca E, Gatti G, Cipolla G, et al. (1994) Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clinical Pharmacology and Therapeutics, 56, 471-476.
24. 24. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. Journal of Clinical Psychopharmacology, 15, 125-131.
25. 25. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG. (1989) Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatrica Scandinavica, Supplement, 350, 102-106.
26. 26. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. (1994) Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23-31.
27. 27. Ketter TA, Flockhart DA, Post RM, et al. (1995) The emerging role of cytochrome P450, 3A in psychopharmacology. Journal of Clinical Psychopharmacology, 15, 387-398.
28. 28. Ereshefsky L, Riesenman C, Lam YW. (1996) Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. Journal of Clinical Psychiatry, 57(Suppl. 8), 17-24.
29. 29. Somogyi A, Gugler A. (1982) Drug interactions with cimetidine. Clinical Pharmacokinetics, 7, 23-41.
30. 30. Somogyi A, Muirhead M. (1987) Pharmacokinetic interactions of cimetidine 1987. Clinical Pharmacokinetics, 12, 321-366.
31. 31. Maurice M, Pichard L, Daujat M, et al. (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB Journal, 6, 752-758.
32. 32. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. (1991) Differential inhibition of individual human liver cytochrornes P-450 by cimetidine. Gastroenterology, 101, 1680-1691.
33. 33. Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. (1985) Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. International Journal of Clinical Pharmacology, Therapy and Toxicology, 23, 447-451.
34. 34. Unge P, Andersson T. (1997) Drug interactions with proton pump inhibitors. Drug Safety, 16, 171-179.
35. 35. Negro RD. (1998) Pharmacokinetic drug interactions with anti-ulcer drugs. Clinical Pharmacokinetics, 35, 135-150.
36. 36. Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. (1990) Effect of omeprazole and cimetidine on plasma diazepam levels. European Journal of Clinical Pharmacology, 39, 51-54.
37. 37. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. (1990) Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clinical Pharmacology and Therapeutics, 47, 79-85.
38. 38. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. (1995) Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clinical Pharmacology and Therapeutics, 58, 127-131.
39. 39. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. (1995) Interaction between grapefruit juice and midazolam in humans. Clinical Pharmacology and Therapeutics, 58, 20-28.
40. 40. Vanakoski J, Mattila MJ, Seppala T. (1996) Grapefruit juice does not enhance the effects of midazolam and triazolam in man. European Journal of Clinical Pharmacology, 50, 501-508.
41. 41. Johannessen SI, Strandjord RE, Munthe-Kaas AW. (1977) Lack of effect of clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine. Acta Neurologica Scandinavica, 55, 506-512.
42. 42. Khoo KC, Mendels J, Rothbart M, et al. (1980) Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam. Clinical Pharmacology and Therapeutics, 28, 368-375.
43. 43. Arana GW, Epstein S, Molloy M, Greenblatt DJ. (1988) Carbamazepine-induced reduction of plasma alprazolam concentrations: a clinical case report. Journal of Clinical Psychiatry, 49, 448-449.
44. 44. Samara EE, Granneman RG, Witt GF, Cavanaugh JH. (1997) Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. Journal of Clinical Pharmacology, 37, 442-450.
45. 45. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. (1995) Interaction of triazolam and ketoconazole. Lancet, 345, 191.
46. 46. Varhe A, Olkkola KT, Neuvonen PJ. (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics, 56 (6 Part 1), 601-607.
47. 47. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. (1994) Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23-31.
48. 48. Olkkola KT, Backman JT, Neuvonen PJ. (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics, 55, 481-485.
49. 49. Ahonen J, Olkkola KT, Neuvonen PJ. (1996) The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundamental and Clinical Pharmacology, 10, 314-318.
50. 50. Ahonen J, Olkkola KT, Neuvonen PJ. (1996) Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Therapeutic Drug Monitoring, 18, 124-127.
51. 51. von Rosensteil NA, Adam D. (1995) Macrolide antibacterials. Drug interactions of clinical significance. Drug Safely, 13, 105-122.
52. 52. Watkins VS, Polk RE, Stotka JL. (1997) Drug interactions of macrolides: emphasis on dirithromycin. Annals of Pharmacotherapy, 31, 349-356.
53. 53. Pessayre D, Descatoire V, Tinel M, Larrey D. (1982) Self-induction by olenndomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Comparison with troleandomycin. Journal of Pharmacology and Experimental Therapeutics, 221, 215-221.
54. 54. Nahata M. (1996) Drug interactions with azithromycin and the macrolides: an overview. Journal of Antimicrobial Chemotherapy, 37(Suppl. C), 133-142.
55. 55. Gurevitz SL. (1997) Erythromycin: drug interactions. Journal of Dental Hygiene, 71, 159-161.
56. 56. Phillips JP, Antal EJ, Smith RB. (1986) A. pharmacokinetic drug interaction between erythromycin and triazolam. Journal of Clinical Psychopharmacology, 6, 297-299.
57. 57. Warot D, Bergougnan L, Lamiable D, et al. (1987) Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. European Journal of Clinical Pharmacology, 32, 389-393.
58. 58. Gascon MP, Dayer P, Waldvogel F. (1989) Les interactions medicamenteuese du midazolam [French]. Schweizerische Medizinische Wochenschrift, 119, 1834-1836.
59. 59. Olkkola KT, Aranko K, Luurila H, et al. (1993) A potentially hazardous interaction between erythromycin and midazolam. Clinical Pharmacology and Therapeutics, 53, 298-305.
60. 60. Wood M. (1991) Midazolam and erythromycin. British Journal of Anaesthesia, 67, 131.
61. 61. Hiller A, Olkkola KT, Isohanni P, Saarnivaara L. (1990) Unconsciousness associated with midazolam and erythromycin. British Journal of Anaesthesia, 65, 826-828.
62. 62. Narchi P, Benhamou D, Elhaddoury M, Locatelli C, Fernandez H. (1993) Interactions of pre-operative erythromycin administration with general anaesthesia. Canadian Journal of Anaesthesia, 40 (5 Part 1), 444-447.
63. 63. Mattila MJ, Idanpaan-Heikkila JJ, Tornwall M, Vanakoski J. (1993) Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. Pharmacology and Toxicology, 73, 180-185.
64. 64. Backman JT, Aranko K, Himberg JJ, Olkkola KT. (1994) A pharmacokinetic interaction between roxithromycin and midazolam. European Journal of Clinical Pharmacology, 46, 551-555.
65. 65. Lieber CS. (1994) Mechanisms of ethanol-drug-nutrition interactions. Journal of Toxicology - Clinical Toxicology, 32, 631-681.
66. 66. Lieber CS. (1994) Susceptibility to alcohol-related liver injury. Alcohol and Alcoholism, Suppl. 2, 315-326.
67. 67. Kitson KE. (1996) Ethanol and acetaldehyde metabolism. Past, present and future. Alcoholism, Clinical and Experimental Research, 20(Suppl. 8), 82A-92A.
68. 68. Asai H, Imaoka S. (1996) Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s. Journal of Pharmacology and Experimental Therapeutics, 277, 1004-1009.
69. 69. Song BJ. (1996) Ethanol-inducible cytochrome P450 (CYP2E1). biochemistry, molecular biology and clinical relevance. 1996 up-date. Alcoholism, Clinical and Experimental Research, 20(Suppl. 8), 138A-146A.
70. 70. Sellers EM, Holloway MR. (1978) Drug kinetics and alcohol ingestion. Clinical Pharmacokinetics, 3, 440-452.
71. 71. Linnoila M, Mattila MJ, Kitchell BS. (1979) Drug interactions with alcohol. Drugs, 18, 299-311.
72. 72. Sellers EM, Busto U. (1982) Benzodiazepines and ethanol: assessment of the effects and consequences of psychotropic drug interactions. Journal of Clinical Psychopharmacology, 2, 249-262.
73. 73. Muhoberac BB, Roberts RK, Hoyumpa AM, Scgenker S. (1984) Mechanism(s) of ethanol-drug interaction. Alcoholism, Clinical and Experimental Research, 8, 583-593.
74. 74. Hoyumpa AM. (1984) Alcohol interactions with benzodiazepines and cocaine. Advances in Alcohol and Substance Abuse, 3, 21-31.
75. 75. Lane EA, Guthrie S, Linnoila M. (1985) Effects of ethanol on drug and metabolite pharmacokinetics. Clinical Pharmacokinetics, 10, 228-247.
76. 76. Guthrie SK, Lane EA. (1986) Reinterpretation of the pharmacokinetic mechanism of oral benzodiazepine ethanol interaction. Alcoholism, Clinical and Experimental Research, 10, 686-690.
77. 77. Mattila MJ. (1990) Alcohol and drug interactions. Annals of Medicine, 22, 363-369.
78. 78. Hollister LE. (1990) Interactions between alcohol and benzodiazepines. Recent Developments in Alcoholism, 8, 233-239.
79. 79. Tanaka E, Misawa S. (1998) Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines, and tricyclic and tetracyclic antidepressants - an update. Journal of Clinical Pharmacy and Therapeutics, 23, 331-336.
80. 80. Sellman R, Kanto J, Raijola E, Pekkarinen A. (1975) Human and animal study on elimination from plasma and metabolism of diazepam after chronic alcohol intake. Acta Pharmacologica et Toxicologica, 36, 33-38.
81. 81. Jusko WJ. (1978) Role of tobacco smoking in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 6, 7-39.
82. 82. Schein JR. (1995) Cigarette smoking and clinically significant drug interactions. Annals of Pharmacotherapy, 29, 1139-1148.
83. 83. Ochs HR, Greenblatt DJ, Knuchel M. (1985) Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. Chest, 87, 223-226.
84. 84. Ochs HR, Greenblatt DJ, Locniskar A, Weinbrenner J. (1986) Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. Klinische Wochenschrift, 64, 1217-1221.
85. 85. Ochs HR, Greenblatt DJ, Burstein ES. (1987) Lack of influence of cigarette smoking on triazolam pharmacokinetics. British Journal of Clinical Pharmacology, 23, 759-763.
86. 86. Ochs HR, Greenblatt DJ, Verburg-Ochs B. (1985) Effect of alprazolam on digoxin kinetics and creatinine clearance. Clinical Pharmacology and Therapeutics, 38, 595-598.
87. 87. Guven H, Tuncok Y, Guneri S, Cavdar C, Fowler J. (1993) Age-related digoxin-alprazolam interaction. Clinical Pharmacology and Therapeutics, 54, 42-44.
88. 88. Castillo-Ferrando JR, Garcia M, Carmona J. (1980) Digoxin levels and diazepam. Lancet, 2, 368.
89. 89. Ochs HR, Greenblatt DJ, Verburg-Ochs B. (1984) Propranolol interactions with diazepam, lorazepam, and alprazolam. Clinical Pharmacology and Therapeutics, 36, 451-155.
90. 90. von Moltke LL, Manis M, Harmatz JS, Poorman R, Greenblatt DJ. (1993) Inhibition of acetaminophen and lorazepam glucuronidation in vitro by probenecid. Biopharmaceutics and Drug Disposition, 14, 119-130.
91. 91. Abernethy DR, Greenblatt DJ, Ameer B, Shader RI. (1985) Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. Journal of Pharmacology and Experimental Therapeutics, 234, 345-349.
92. 92. Back DJ, Orme ML. (1990) Pharmacokinetic drug interactions with oral contraceptives. Clinical Pharmacokinetics, 18, 472-484.
93. 93. Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB. (1984) Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clinical Pharmacology and Therapeutics, 36, 683-690.
94. 94. Abernethy DR, Greenblatt DJ, Divoll M, Arendt R, Ochs HR, Shader RI. (1982) Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids. New England Journal of Medicine, 306, 791-792.
95. 95. Jochemsen R, van der Graaff M, Boeijinga JK, Breimer DD. (1982) Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. British Journal of Clinical Pharmacology, 13, 319-324.